{"id":5548,"date":"2022-06-17T15:54:30","date_gmt":"2022-06-17T14:54:30","guid":{"rendered":"https:\/\/touchimmunology.com\/?post_type=media_gallery&#038;p=5548"},"modified":"2022-06-17T15:54:30","modified_gmt":"2022-06-17T14:54:30","slug":"marla-c-dubinsky-ddw-2022-lucent-2-study-mirikizumab-maintenance-therapy-in-moderate-to-severe-ulcerative-colitis-part-2","status":"publish","type":"media_gallery","link":"https:\/\/touchimmunology.com\/digestive-disorders\/conference-hub\/marla-c-dubinsky-ddw-2022-lucent-2-study-mirikizumab-maintenance-therapy-in-moderate-to-severe-ulcerative-colitis-part-2\/","title":{"rendered":"Marla C. Dubinsky, DDW 2022: LUCENT-2 Study \u2013 Mirikizumab Maintenance Therapy in Moderate-to-Severe Ulcerative Colitis (Part 2)"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">The LUCENT-2 study (ClinicalTrials.gov Identifier: <a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03524092\" rel=\"nofollow noopener\" target=\"_blank\">NCT03524092<\/a>) is a maintenance study of mirikizumab in patients with moderate-to-severe ulcerative colitis (UC).<\/span><span style=\"font-weight: 400;\"> touchIMMUNOLOGY caught up with <strong>Prof. Marla C. Dubinsky<\/strong> (Icahn School of Medicine, Mount Sinai, New York, NY, USA) to find out the efficacy and safety findings of the study and where mirikizamab would fit in the treatment paradigm for UC, if approved.<\/span><\/p>\n<p>The abstract \u2018<em>EFFICACY AND SAFETY OF MIRIKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-2 STUDY.<\/em>\u2018 was presented at <a href=\"https:\/\/ddw.org\/\" target=\"_blank\" rel=\"nofollow noopener\">Digestive Disease Week 2022<\/a>, May 21-24, 2022.<\/p>\n<p><b>Questions<\/b><\/p>\n<ol>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">What were the efficacy and safety findings of the study? (0:20)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">If approved, where do you see mirikizamab sitting in the expanding treatment paradigm for ulcerative colitis? (9:54)<\/span><\/li>\n<\/ol>\n<p><b>Disclosures:<\/b><span style=\"font-weight: 400;\"> Marla C. Dubinsky discloses consulting and serving on advisory boards for Lilly.<\/span><\/p>\n<p><b>Support:<\/b><span style=\"font-weight: 400;\"> Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.<\/span><\/p>\n<p><b><i>Filmed in coverage of DDW 2022.<\/i><\/b><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The LUCENT-2 study (ClinicalTrials.gov Identifier: NCT03524092) is a maintenance study of mirikizumab in patients with moderate-to-severe ulcerative colitis (UC). touchIMMUNOLOGY caught up with Prof. Marla C. Dubinsky (Icahn School of Medicine, Mount Sinai, New York, NY, USA) to find out the efficacy and safety findings of the study and where mirikizamab would fit in the [&hellip;]<\/p>\n","protected":false},"featured_media":5543,"template":"","class_list":["post-5548","media_gallery","type-media_gallery","status-publish","has-post-thumbnail","hentry","vocabulary_1-digestive-disorders","video_categories-ddw"],"acf":[],"_links":{"self":[{"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media_gallery\/5548","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media_gallery"}],"about":[{"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/types\/media_gallery"}],"version-history":[{"count":5,"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media_gallery\/5548\/revisions"}],"predecessor-version":[{"id":5613,"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media_gallery\/5548\/revisions\/5613"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media\/5543"}],"wp:attachment":[{"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media?parent=5548"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}